Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/08/2022 -- Results Q4 2021 -- -0.13 --
03/08/2022 16:30 EST Earnings Call Q4 2021 -- -- --
11/04/2021 -- Results Q3 2021 -0.15 -0.12 -29.31%
11/04/2021 16:30 EST Earnings Call Q3 2021 -- -- --
08/03/2021 -- Results Q2 2021 -0.11 -0.05 -129.2%
08/03/2021 16:30 EST Earnings Call Q2 2021 -- -- --
05/04/2021 -- Results Q1 2021 -0.10 -0.06 -72.41%
05/04/2021 16:45 EST Earnings Call Q1 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 03/08/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/04/2021
Beat/Miss Upgrade
Return Since -44.35%
Last FQE 09/30/2021
Next FQE 12/30/2021

Profile

Edit
CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend, K ontrol, and DrugSorb. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending.
URL https://www.cytosorbents.com
Investor Relations URL https://cytosorbents.com/investor-relations/overview
HQ State/Province New Jersey
Sector Healthcare
Industry Medical Devices
Equity Style Small Cap/Growth
Next Earnings Release Mar. 08, 2022
Last Earnings Release Nov. 04, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-44.02%
-2.15%
19.27%
24.31%
-52.35%
107.0%
-47.43%
-18.85%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-7.66%
--
--
-0.37%
-2.63%
-64.63%
-4.83%
206.3%
-2.62%
--
--
--
--
--
54.43%
18.78%
-26.75%
-58.68%
-88.50%
-99.97%
-99.39%
-89.16%
-15.67%
-56.75%
-13.55%
38.79%
-10.12%
-45.41%
-76.01%
-54.39%
38.08%
-28.97%
-50.98%
As of January 21, 2022.

Profile

Edit
CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend, K ontrol, and DrugSorb. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending.
URL https://www.cytosorbents.com
Investor Relations URL https://cytosorbents.com/investor-relations/overview
HQ State/Province New Jersey
Sector Healthcare
Industry Medical Devices
Equity Style Small Cap/Growth
Next Earnings Release Mar. 08, 2022
Last Earnings Release Nov. 04, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
CSGOX 174150.0 USD 4.22%
WPSMX 334950.0 USD 4.00%
WPLCX 378015.0 USD 1.10%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Stocktwits CTSO Tweets